Charting A Successful CMC Journey For Your ADC Drug Product

Bioconjugates and Antibody-Drug Conjugates (ADCs) are transforming cancer treatment with their targeted approach. However, their complex nature presents manufacturing challenges, especially for highly potent ADCs.

Discover best practices and strategies for optimizing bioconjugate drug product tech transfers and supplies in clinical or commercial phases. We delve into real-world case studies, including:

• Accelerating Clinical Tech Transfer: Innovative solutions and science-driven development approaches
• Tailored Approaches: Flexible entry points, stand-alone, and integrated bioconjugates drug substance/drug product solutions
• High-Potency Biologics Manufacturing: Overcoming the unique challenges and intricacies of high-containment manufacturing for ADCs

Key Learning Objectives:

• Explore best practices and case studies in bioconjugate and ADC drug product development and manufacturing
• Learn about Lonza's new Drug Product High Potent capabilities from pre-clinical to commercial supply
• Discover flexible entry points with tailored approaches for every ADC phase